GSK's Wellcovorin Tablets Approved by FDA for Expanded Use
MT Newswires Live
Mar 10
GSK's (GSK) Wellcovorin tablets have been approved by the US Food and Drug Administration for expanded use, the regulator said Tuesday.
Wellcovorin is intended to treat cerebral folate deficiency in adult and pediatric patients with a variant in the folate receptor 1 gene, according to the FDA.
The regulator said its approval was based on a review of published literature on the topic, including case reports with patient-level information, and mechanistic data. According to the FDA, patients with the disorder often have severe developmental delays, movement disorders, seizures, and other neurological complications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.